What is HC Wainwright’s Estimate for ESPR FY2028 Earnings?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Analysts at HC Wainwright upped their FY2028 earnings per share (EPS) estimates for Esperion Therapeutics in a research note issued to investors on Tuesday, January 13th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will post earnings of $1.07 per share for the year, up from their previous forecast of $0.90. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share.

Several other research firms also recently commented on ESPR. Wall Street Zen raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Piper Sandler started coverage on Esperion Therapeutics in a research note on Tuesday, November 25th. They set an “overweight” rating and a $9.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Esperion Therapeutics in a report on Wednesday, November 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Wednesday, October 8th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $7.20.

Esperion Therapeutics Trading Down 7.0%

ESPR opened at $3.30 on Wednesday. Esperion Therapeutics has a 1-year low of $0.69 and a 1-year high of $4.18. The company has a market cap of $788.90 million, a price-to-earnings ratio of -6.60, a PEG ratio of 10.87 and a beta of 1.04. The company’s fifty day moving average price is $3.56 and its two-hundred day moving average price is $2.65.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.07). The company had revenue of $87.31 million for the quarter, compared to analyst estimates of $78.33 million.

Insider Buying and Selling

In other Esperion Therapeutics news, CFO Benjamin Halladay sold 7,337 shares of Esperion Therapeutics stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total transaction of $26,926.79. Following the transaction, the chief financial officer owned 467,525 shares of the company’s stock, valued at $1,715,816.75. This trade represents a 1.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.70% of the company’s stock.

Hedge Funds Weigh In On Esperion Therapeutics

Institutional investors have recently modified their holdings of the business. DHJJ Financial Advisors Ltd. increased its position in shares of Esperion Therapeutics by 209.2% during the third quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 6,380 shares during the last quarter. North Star Investment Management Corp. bought a new position in Esperion Therapeutics in the 2nd quarter valued at $25,000. Sivia Capital Partners LLC bought a new position in Esperion Therapeutics in the 2nd quarter valued at $25,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Esperion Therapeutics during the 3rd quarter valued at $29,000. Finally, R Squared Ltd bought a new stake in shares of Esperion Therapeutics during the 3rd quarter worth $33,000. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.